AbbVie is set to acquire Nimble Therapeutics, an oral peptide developer spun out from Roche, for $200 million, with potential milestone payments. Nimble, led by former Roche scientist Jigar Patel, is developing three drug candidates targeting autoimmune diseases, including therapies for generalized myasthenia gravis, psoriasis, and inflammatory bowel disease. The acquisition will enhance AbbVie's capabilities in peptide drug development, positioning it to better address the needs of patients with autoimmune conditions.
